{rfName}

Indexed in

License and use

Altmetrics

Grant support

This research was supported by CIBER-Consorcio Centro de Investigacion Biomedica en Red (CIBERES), the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovacion and the European Union's European Regional Development Fund.

Analysis of institutional authors

Sibila OAuthor
Share
Publications
>
Article

Peripheral Neutrophil-to-Lymphocyte Ratio in Bronchiectasis: A Marker of Disease Severity

Publicated to:Biomolecules. 12 (10): 1399- - 2022-10-01 12(10), DOI: 10.3390/biom12101399

Authors: Angel Martinez-Garcia, Miguel; Olveira, Casilda; Giron, Rosa; Garcia-Clemente, Marta; Maiz-Carro, Luis; Sibila, Oriol; Golpe, Rafael; Mendez, Raul; Rodriguez Hermosa, Juan Luis; Barreiro, Esther; Prados, Concepcion; Rodriguez Lopez, Juan; de la Rosa, David

Affiliations

Hosp Clin Barcelona, Serv Neumol, IDIBAPS, Barcelona 08036, Spain - Author
Hosp La Paz, Serv Neumol, Madrid 28046, Spain - Author
Hosp Lucus Augusti, Serv Neumol, Lugo 27003, Spain - Author
Hosp Ramon & Cajal, Serv Neumol, Madrid 28034, Spain - Author
Hosp San Agustin, Serv Neumol, Aviles 33410, Asturias, Spain - Author
Hosp Santa Creu & Sant Pau, Serv Neumol, Barcelona 08041, Spain - Author
Hosp Univ & Politecn La Fe, Inst Invest La Fe IISLAFE, Valencia 46026, Spain - Author
Hosp Univ & Politecn La Fe, Serv Neumol, Valencia 46026, Spain - Author
Hosp Univ la Princesa, Inst Invest Sanitaria, Serv Neumol, Madrid 28006, Spain - Author
Inst Invest Biosanitaria Principado Asturias ISPA, Serv Neumol, Oviedo 33011, Spain - Author
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp, Madrid 28220, Spain - Author
Univ Complutense Madrid, Res Inst Hosp Clin San Carlos IdISSC, Fac Med, Pulm Dept, Madrid 28040, Spain - Author
Univ Malaga, Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, Serv Neumol, Malaga 29010, Spain - Author
UPF, Serv Neumol, CIBERES, Hosp del Mar IMIM, Barcelona 08003, Spain - Author
See more

Abstract

Most patients with bronchiectasis have a predominantly neutrophilic inflammatory profile, although other cells such as lymphocytes (as controllers of bronchial inflammation) and eosinophils also play a significant pathophysiological role. Easy-to-interpret blood biomarkers with a discriminative capacity for severity or prognosis are needed. The objective of this study was to assess whether the peripheral neutrophil-to-lymphocyte ratio (NLR) is associated with different outcomes of severity in bronchiectasis. A total of 1369 patients with bronchiectasis from the Spanish Registry of Bronchiectasis were included. To compare groups, the sample was divided into increasing quartiles of NLR ratio. Correlations between quantitative variables were established using Pearson's P test. A simple linear regression (with the value of exacerbations as a quantitative variable) was used to determine the independent relationship between the number and severity of exacerbations and the NLR ratio. The area under the curve (AUC)-ROC was used to determine the predictive capacity of the NLR for severe bronchiectasis, according to the different multidimensional scores. Mean age: 69 (15) years (66.3% of women). The mean NLR was 2.92 (2.03). A higher NLR was associated with more severe bronchiectasis (with an especially significant discriminative power for severe forms) according to the commonly used scores (FACED, E-FACED and BSI), as well as with poorer quality of life (SGRQ), more comorbidities (Charlson index), infection by pathogenic microorganisms, and greater application of treatment. Furthermore, the NLR correlated better with severity scores than other parameters of systemic inflammation. Finally, it was an independent predictor of the incident number and severity of exacerbations. In conclusion, the NLR is an inexpensive and easy-to-measure marker of systemic inflammation for determining severity and predicting exacerbations (especially the most severe) in patients with bronchiectasis.

Keywords
biomarkersbronchiectasiscluster-analysiscopdexacerbationexacerbationslymphocytemicrobiomeseveritysystemic inflammationAgedArea under the curveArticleBiological markerBiomarkersBody massBronchiectasisC reactive proteinCharlson comorbidity indexComputer assisted tomographyCorticosteroidCystic fibrosis bronchiectasisDisease exacerbationDisease severityDyspneaExacerbationsFemaleHaemophilus influenzaeHemoptysisHospitalizationHumanHuman cellHumansInflammationLinear regression analysisLongitudinal studyLymphocyteLymphocyte countLymphocytesMacrolideMajor clinical studyMaleMean platelet volumeMicroorganismMulticenter studyNeutrophilNeutrophil lymphocyte ratioNeutrophilsObservational studyOutcome assessmentOxygen saturationPseudomonas aeruginosaQuality of lifeReceiver operating characteristicRetrospective studyRoc curveSeveritySeverity of illness indexSt. george respiratory questionnaireStaphylococcus aureus

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Biomolecules due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 70/285, thus managing to position itself as a Q1 (Primer Cuartil), in the category Biochemistry & Molecular Biology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 2.93. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 2.5 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 9.26 (source consulted: Dimensions Apr 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-04-25, the following number of citations:

  • WoS: 14
  • Scopus: 15
  • Europe PMC: 1
  • OpenCitations: 12
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-04-25:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 18.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 18 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 2.
  • The number of mentions on the social network X (formerly Twitter): 4 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.